We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The National Institutes of Health (NIH) has enlisted the help of 11 top-tier biopharma companies as it pushes towards the goal of cutting the time it takes to bring new cancer immunotherapies to patients in half.